Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

E. Zhu | Researchclopedia

Back to researchers

E. Zhu

AbbVie (United States)

7

Works

1,724

Citations

3

h-index

2

i10-index

Research Topics

Lymphoma Diagnosis and Treatment Ovarian cancer diagnosis and treatment Tuberculosis Research and Epidemiology

Affiliations

AbbVie (United States)2025–2025

Janssen (United States)2019–2019

Top Works

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

B Coiffier,E.A. Osmanov,et al.

20111,622 citations

Lung Cancer Treatments and Mutations

Prostate Cancer Treatment and Research

Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

Matthew R. Smith,Shahneen Sandhu,et al.

201994 citations

PS1456 FAVORABLE OVERALL SURVIVAL OF IMETELSTAT‐TREATED RELAPSED/REFRACTORY MYELOFIBROSIS PATIENTS COMPARED WITH CLOSELY MATCHED REAL WORLD DATA

Andrew Kuykendall,Ying Wan,et al.

20195 citations

Efficacy and safety of bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed, R-naive/-sensitive follicular lymphoma (FL): outcome according to prior therapy

M. Crump,Adriana Scheliga,et al.

20112 citations

FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation

Eva Kimby,Adriana Scheliga,et al.

20111 citations

[X-ray manifestations of 100 elderly cases of pulmonary tuberculosis].

E. Zhu,Jinqin Jiang,et al.

19820 citations

1948P Treatment outcomes in patients (pts) with advanced c-Met overexpressing (OE) EGFR wildtype (WT) nonsquamous (NSQ) NSCLC who had telisotuzumab vedotin (Teliso-V) dose modifications in the LUMINOSITY trial

Aaron S. Mansfield,S. Lu,et al.

20250 citations